Ambrisentan 1267 5-a]pyrimidinescaffold of dorsomorphin: the discovery

5-a]pyrimidinescaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selectiveMLPCN probe

which results in increased HDL-C

Smiles: CCCOC1C=CC(CCC2=NC3=CC(=CC=C3N2CCN2CCOCC2)C2C(C)=NOC=2C)=CC=1

CAS Number: 1173022-16-6

InChi: InChI=1S/C47H56ClFN8O8/c1-54-42(59)16-15-37(46(54)61)57-45(60)32-11-9-12-38(43(32)47(57)62)64-25-8-6-4-3-5-7-18-50-41(58)17-20-56-23-21-55(22-24-56)19-10-26-65-40-28-33-36(29-39(40)63-2)51-30-52-44(33)53-31-13-14-35(49)34(48)27-31/h9

Ambrisentan 1267 5-a]pyrimidinescaffold of dorsomorphin: the discoveryAmbrisentan, also known as BSF 208075 and LU 208075, is a drug indicated for use in the treatment of pulmonary hypertension. Ambrisentan, which relaxes those muscles, is an endothelin receptor antagonist, and is selective for the type A endothelin receptor (ETA). Ambrisentan significantly improved exercise capacity (6 minute walk distance) compared with placebo in two double blind, multicenter trials (ARIES 1 and ARIES 2). Ambrisentan was approved by